// App-Quantinova.ai

818 : Excretion of WTX101 (bis‐choline tetrathiomo‐ lybdate) after intravenous administration in rat models

Researchers

Presenter

  • Tom Plltz

Principal Investigators

  • Lee Boyling

Medical Centers

  • Wilson Therapeutics, Stockholm, Sweden

  • Arcinova, Alnwick, United Kingdom

Locations

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Wilson disease

Biomarkers

  • Human albumin

Drug/Treatment

  • Tetrathiomolybdate

  • Molybdenum

  • Choline bitartrate

  • WTX 101

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved